Special Issue

In Vivo Mouse Models of Human Viral Infections

Message from the Guest Editors

The use of in vivo mouse models of human viral infections has been integral to advancing knowledge of these pathogens and diseases. Mouse models of many human viral infections, including sexually transmitted viruses such as HIV and HSV-2, respiratory transmitted viruses such as Influenza and SARS-CoV2 and emerging infections such as ZIKA virus and EBOLA have laid the ground work for examining pathogenesis, therapeutics, vaccines, and immune responses. As new pathogens emerge, researchers have responded by creating in vivo models to ask the questions that are challenging to study in human studies. New innovations in *in vivo* models such as use of transgenic mice in Zika have been used to examine sexual transmission of this virus and its effects in pregnancy. Humanized mice have enabled the examination of HIV pathogenesis and therapeutics and rapid advances in these models are allowing investigation into more complex areas such as latency and vaccination. In this issue, we hope to develop a collection of papers using mouse model systems to generate new knowledge about human viral infections.

Guest Editors

Prof. Charu Kaushic

Department of Medicine, McMaster Immunolgy Research Center, McMaster University, Hamilton, Canada

Dr. Amy Gillgrass

Department of Medicine, McMaster Immunology Research Centre (MIRC), Institute for Infectious Disease Research (IIDR), McMaster University, Hamilton, Canada

Deadline for manuscript submissions

closed (22 December 2021)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/69775

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).